Volume 30, Number 4—April 2024
Research
Bus Riding as Amplification Mechanism for SARS-CoV-2 Transmission, Germany, 20211
Meike Schöll2, Christoph Höhn2, Johannes Boucsein, Felix Moek, Jasper Plath, Maria an der Heiden, Matthew Huska, Stefan Kröger, Sofia Paraskevopoulou, Claudia Siffczyk, Udo Buchholz3, and Raskit Lachmann3
Table 1
Main characteristics of case-patients in COVID-19 outbreak, by age group, Hesse, Germany, 2021*
| Characteristic | Age, y |
Overall no. (%), n = 191 |
||||||
|---|---|---|---|---|---|---|---|---|
| <6, no. (%), n = 11 | 6–10, no. (%), n = 73 | 11–17, no. (%), n = 28 | 18–40, no. (%), n = 20 | 41–60, no. (%), n = 30 | >60, no. (%), n = 29 | |||
| Sex | ||||||||
| F | 5 (45.5) | 32 (43.8) | 14 (50.0) | 14 (70.0) | 13 (43.3) | 18 (62.1) | 96 (50.3) | |
| M |
6 (54.5) |
41 (56.2) |
14 (50.0) |
6 (30.0) |
17 (56.7) |
11 (37.9) |
95 (49.7) |
|
| Setting | ||||||||
| Household | 7 (63.6) | 5 (6.8) | 18 (64.3) | 19 (95.0) | 27 (90.0) | 9 (31.0) | 85 (44.5) | |
| Bus | 3 (27.3) | 46 (63.0) | 3 (10.7) | 0 | 1 (3.3) | 6 (20.7) | 59 (30.9) | |
| School | 0 | 19 (26.0) | 1 (3.6) | 0 | 0 | 0 | 20 (10.5) | |
| Workplace | 0 | 0 | 0 | 0 | 2 (6.7) | 4 (13.8) | 6 (3.1) | |
| Travel | 0 | 0 | 0 | 0 | 0 | 5 (17.2) | 5 (2.6) | |
| Other | 1 (9.1) | 0 | 2 (7.1) | 1 (5.0) | 0 | 4 (13.8) | 8 (4.2) | |
| Unknown |
0 |
3 (4.1) |
4 (14.3) |
0 |
0 |
1 (3.4) |
8 (4.2) |
|
| Prior SARS-CoV-2 infection | ||||||||
| Yes | 0 | 1 (1.4) | 0 | 0 | 0 | 0 | 1 (0.5) | |
| No |
11 (100) |
72 (98.6) |
28 (100) |
20 (100) |
30 (100) |
29 (100) |
190 (99.5) |
|
| Symptomatic infection | ||||||||
| Yes | 7 (63.6) | 62 (84.9) | 23 (82.1) | 20 (100) | 26 (86.7) | 22 (75.9) | 160 (83.8) | |
| No | 4 (36.4) | 11 (15.1) | 5 (17.9) | 0 | 4 (13.3) | 6 (20.7) | 30 (15.7) | |
| Value missing |
0 |
0 |
0 |
0 |
0 |
1 (3.4) |
1 (0.5) |
|
| Severity of disease, most severe status selected | ||||||||
| No treatment | 9 (81.8) | 58 (79.5) | 14 (50.0) | 12 (60.0) | 17 (56.7) | 15 (51.7) | 125 (65.4) | |
| Outpatient treatment | 0 | 6 (8.2) | 0 | 3 (15.0) | 5 (16.7) | 0 | 14 (7.3) | |
| Inpatient treatment | 0 | 0 | 1 (3.6) | 1 (5.0) | 0 | 3 (10.3) | 5 (2.6) | |
| Treatment in ICU | 0 | 0 | 0 | 0 | 2 (6.7) | 0 | 2 (1.0) | |
| Deceased | 0 | 0 | 0 | 0 | 0 | 4 (13.8) | 4 (2.1) | |
| Value missing |
2 (18.2) |
9 (12.3) |
13 (46.4) |
4 (20.0) |
6 (20.0) |
7 (24.1) |
41 (21.5) |
|
| COVID-19 vaccination status | ||||||||
| Fully vaccinated | 0 | 0 | 0 | 10 (50.0) | 14 (46.7) | 19 (65.5) | 43 (22.5) | |
| Not or not fully vaccinated | 11 (100) | 73 (100) | 28 (100) | 10 (50.0) | 16 (53.3) | 10 (34.5) | 148 (77.5) |
|
*The variable on severity of disease combines information from the routine surveillance system with survey results, resulting in a high number of missing values. ICU, intensive care unit.
1Preliminary results from this study were presented at the ESCAIDE conference; November 24, 2022; Stockholm, Sweden.
2These first authors contributed equally to this article.
3These senior authors contributed equally to this article.
Page created: March 01, 2024
Page updated: March 20, 2024
Page reviewed: March 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.